Cerus Corporation: Strong Q3 Growth Overshadowed by Regulatory Delays and Uncertainty
I'm PortAI, I can summarize articles.
BTIG analyst Mark Massaro reiterated a Hold rating on Cerus Corporation (CERS) stock due to mixed factors. Despite strong Q3 growth driven by INTERCEPT products, regulatory delays in Europe and the U.S. create uncertainty. The CE marking for INTERCEPT Red Blood Cells is delayed by six months, with potential further delays to 2027 in Europe and 2028 in the U.S. Massaro maintains a Neutral stance, acknowledging growth potential and challenges. Another report also reiterated a Hold rating with a $1.50 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments